Stivarga Tablet, Film Coated
Product Images NDC 50419-171

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Stivarga (NDC 50419-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Main Display Panel Commercial Carton 40 mg (Image 01)

Packaging label for Stivarga (regorafenib) tablets 40 mg by Bayer HealthCare Pharmaceuticals Inc. The label states the product is for oral administration with a package size of 3 x 28 tablets. The label includes dosage form as film-coated tablets and the NDC 50419-171-03. It has a teal wave design with the brand and generic names prominently displayed.*

FDA Label Image

Description: Chemical Structure (Image 02)

Chemical structure of regorafenib, the active ingredient in Stivarga 40 mg film-coated tablets. The diagram displays the molecular arrangement including aromatic rings, functional groups, and atoms such as chlorine, fluorine, oxygen, nitrogen, and a water molecule (H2O).*

FDA Label Image

Stivarga Gist Uspi Figure 1 V3 (Image 03)

A survival probability Kaplan-Meier curve comparing Stivarga (regorafenib) versus placebo over approximately 14 months from randomization. The y-axis shows survival probability percentage, and the x-axis shows months. The graph includes numbers of patients at risk over time for each group, with Stivarga represented by a solid black line (N=505) and placebo by a dashed gray line (N=255).*

FDA Label Image

Stivarga Gist Uspi Figure 2 V3 (Image 04)

A Kaplan-Meier survival curve showing progression-free survival probability (%) over months from randomization comparing Stivarga (regorafenib) and placebo groups. Stivarga group (N=133) is represented by a solid line, and placebo group (N=66) by a dashed line. The graph includes number of patients at risk at specified time points for both groups.*

FDA Label Image

Fig 3 Curve Of Overall Survival (Image 05)

A Kaplan-Meier survival probability curve comparing Stivarga (regorafenib) tablets 40 mg to placebo over time. The y-axis shows survival probability (%) from 0 to 100%, and the x-axis shows months from randomization up to 33 months. The solid line represents Stivarga (n=379), and the dashed line represents placebo (n=194). Numbers of patients at risk at different time points are shown below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.